Mealey's (July 25, 2022, 2:11 PM EDT) -- PHILADELPHIA — A federal district court did not err in dismissing shareholder claims alleging that a commercial-stage biopharmaceutical company and its board of directors violated federal securities law by failing to disclose information material to shareholders’ vote on a proposed merger deal because the alleged misrepresentations cited by the lead plaintiffs were not plausibly pleaded, a Third Circuit U.S. Court of Appeals panel ruled July 20 in affirming....